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Healthcare expenditure in the United States has grown and will continue to increase. The
increasing healthcare expenditure is to reduce real income as well as to diminish total
utility and increase financial stresses. This study argues that the most critical factor that
increases healthcare expenditures during last 50 years has been the advent, adoption and
diffusion of new medical technologies that include new drugs, equipment and healthcare
delivery systems. This study introduces various examples how medical innovations
influence to increase healthcare expenditures. In company with the advanced medical
technology, this study suggests a free market in medical technology that means less
regulation and less subsidization to healthcare market participants, such as healthcare
providers, insurers, and healthcare consumers to reduce healthcare expenditures.
Keywords: Medical innovation, Healthcare expenditure, Social externalityIntroduction: medical technologies
Healthcare expenditures in the United States have grown from $27.4B (or 5.0% of the
GDP) in 1960 to $2.9 trillion (or 16.4% of the GDP) in 2013. Out of that amount in
2013, 53% was financed by private insurances and out–of-pocket payments from
consumers, while 47% came from public health programs, such as Medicare, Medicaid
and other federal or state healthcare programs (CBO, 2015). The Congressional Budget
Office (CBO) estimates that national expenditures for healthcare will continue to
increase to about one-quarter of GDP by 2040 (CBO, 2015).
Healthcare expenditures per capita in the United States have increased from $125, or
5.6% of per capita income ($2219), in 1960 to $7826, or 18.8% of per capita income
($41,706), in 2013 (CDC, 2015). The healthcare expenditure per person, as well as the
healthcare expenditure portion of personal income, have grown and will continue to in-
crease. The effect of such increasing healthcare expenditures is to reduce real income. Such
income reductions diminish total utility and increase financial stresses, especially among
low income groups. One in five American adults is struggling to pay his healthcare bills,
and over 62% of all personal bankruptcies have a medical cause (Himmelstein et al., 2009).
Many with coverage are found to be under-insured and to have a responsibility for
thousands of dollars in out-of-pocket expenses. Even though others have private insurance,
they lose it when they become too sick to work. 25% of companies withdraw healthcare
insurance immediately when their employees suffer from illness. Another 25% do so within
1 year (Pereira 2003). The loss of income from illness is common, but can often be coupled
with high healthcare bills. Consequently, the burden of healthcare expenditure is linked to
widespread indebtedness.The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
icense (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
rovided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
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coverage (which has declined as consumers have had to pay a greater share of medical
expenses out-of-pocket), the most critical factor that has influenced the rise of per
capita healthcare expenditures during the past 50 years has been the advent, adoption,
and diffusion of new clinical technologies and healthcare services (CBO, 2008). Such
advanced healthcare technologies allow healthcare professionals to diagnose and treat
patients in methods that were never previously possible. Many of these healthcare
innovations are accompanied with expensive new drugs, equipment, and skills. Other
innovations are relatively inexpensive, but the cost of healthcare innovation has
increased quickly as growing numbers of healthcare professionals and patients have
used them. Even though technical advances in healthcare should reduce expendi-
tures, instead, they have increased total healthcare spending.
Technologic innovations in HealthCare
Medical innovations have made significant contributions to improve the healthcare
community, especially to expand patient longevity over the past 60 years, while health-
care expenditures have grown much faster than the overall economy. Medical innova-
tions can consist of new medical and surgical procedures, such as joint replacement
and angioplasty, equipment such as MRI and implantable defibrillators, and processes
such as electronical medical records and transmission of information, and healthcare
delivery via telemedicine. But innovations in healthcare delivery in the USA have not
taken place and are not needed if the full benefits of innovation are accomplished from
diagnostics, therapeutics, and devices (Aspden, 2002). The US health delivery system
has been fragmented, and has not developed to accommodate the complexities of
healthcare. There has been not enough investment and development in healthcare
information systems. It is critical for the government to lead the development of inno-
vations in healthcare delivery systems. Another characteristic of medical innovation is
that medical devices and drugs have a different paradigms in innovation. Innovations in
medical devices have a significant cost-effective improvement over time rather than
innovations in drugs. For instance, innovations in implantable cardioverter defibrillators
(ICDs) reduced the average cost of a life-year saved from about $50,000 in the mid-1990
to nearly $30,000 currently (Owens et al. 1997; Sanders et al., 2005; Weiss et al., 2002 and
Hsu et al. 2002). Early cost-effectiveness studies for ICDs should be to present worst-case
scenarios and could lead to premature abandonment.
Chandra and Skinner (2012) categorized three types of medical innovations based on
average cost-effectiveness: (1) highly cost effective medical innovation where usage has
a positive externality; (2) medical innovation that is clearly positive for a certain subset
of patients, but that is seriously heterogeneous across populations; and (3) one that has
poor cost-effectiveness for the overall majority of the patient population.
Innovation in healthcare can reduce expenditure in some instances. Certain types of
preventative healthcare, for example, some vaccines, should decrease the chance of
patient hospitalization for acute care, but examples of medical innovation that have
proven long-term savings are few. Incremental innovation to design and production of
healthcare devices can lower costs per unit. Such innovations aim to improve efficiency
through lower-cost and higher quality of products and to develop the design and use of
the device. This kind of innovation is possible from the contribution of developed
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based platform and wireless technologies. These innovations may lead to improved prod-
uctivity because of a reduced unit cost of procedure. On the other hand, these productive
innovations cause an increase in demand for these procedures, drugs, and devices, and
then serve to increase overall healthcare expenditure.
This type of medical innovation is cost-effective and useful for the relevant population.
Improved health behaviors are included in this type of medical innovation (Cutler and
Kadiyala, 2003). Antibiotics such as sulphonamide drugs made a contribution to reduce
mortality rates in the early 20th century (Cutler et al., 2006). The advent of these drugs had
extirpated pneumonia, tuberculosis, dysentery, and venereal disease. The development of
low-cost antibiotic drugs made remarkable improvements in outcomes following outbreaks
of bacterial meningitis (Chandra and Skinner, 2012). Surfactants that treat neonatal acute
respiratory distress for newborn babies are highly cost-effective. These drugs were estimated
to reduce the possibility of mortality by 30% and proved to be protective of costs that
declined by 10% for survivors and 30% for the deceased (Schwartz et al., 1994).
However, these types of medical innovations are not always cost effective. The example is
anti-retroviral drugs for HIV treatment to prevent the development of full-blown AIDS.
Romley and his colleagues analyzed the life expectancy gains of people infected with HIV
between the introduction of cART in 1996 and the 2009 guideline revisions. They concluded
the patients who initiated treatment early could expect to live 6.1 years longer, and the
earliest initiators could have an extra 9.0 years of life. Total value of life expectancy was $80
billion, with each life-year valued at $150,000 from those treatments (Romley et al, 2014).
Another example of successful medical innovation is lung cancer treatment. Ramsey and his
colleagues evaluated the economic impact of new lung cancer treatments alongside
Southwest Oncology group Trial S9509. They estimated the cost-effectiveness of
cisplatin plus vinorelbine versus carboplatin plus paclitaxel for patients with
advanced non-small-cell lung cancer. They concluded that treatment with cisplatin
plus vinorelbine is more cost –effective than treatment with carboplatin plus paclit-
xel (Ramsey et al., 2002). Unfortunately, AIDS and lung cancer treatment cases are
the exception rather than the norm.
The second type of medical innovation is one which is cost-effective for some
patients but of declining marginal benefit for others. Many healthcare innovations
relate to ongoing treatment for the management of chronic conditions such as
diabetes and coronary artery disease. These types of healthcare innovations should
increase costs in many ways (CBO, 2008; Newhouse, 1992). Innovative drugs and
procedures that improve clinical outcomes and heal patients can change healthcare
delivery systems and critical factors to raise healthcare costs. These healthcare
innovations save and extend the lives of patients. They are critically important to
patients as well as to society. For instance, by the middle of 1960s, the treatment
for patients who suffered from coronary artery disease was not expensive, since
caregivers did not do much to help patients. The standard treatment for patients
with a heart attack was bed rest and morphine. Since then, major innovations in
medical technology have made available a series of treatments. Many medical
developments that decrease mortality rate and increase longevity of life increase
healthcare spending, since surviving patients extend their lives and therefore con-
sume healthcare services for more years.
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narrowed coronary arteries (the main blood vessels supplying the heart). This surgery uses
a balloon to stretch open a narrowed or blocked artery. However, most modern
angioplasty procedures also involve inserting a short wire-mesh tube, called a stent, into
the artery during the procedure. The stent is left in place permanently to allow blood to
flow more freely. Coronary angioplasty can save cost per procedure for patients at first,
but its advent actually increases total healthcare costs. Although this procedure provides
the clinical benefits without the risk of open-heart bypass surgery, recurrence of
artery blockage after angioplasty occurs frequently. It leads to many repeat proce-
dures, and some failed angioplasties were followed eventually by bypass surgery.
Total spending for heart disease patients increased after angioplasty was introduced
(Cutler and Huckman 2003). Certain types of medical innovation entail fewer risks.
For example, laporoscopy, a surgical procedure in which a fiber-optic instrument is
inserted through the abdominal wall to view the organs in the abdomen or to
permit a surgical procedure, increases costs not because each procedure is expen-
sive, but because so many more patients may use this procedure. Even though
healthcare costs per patient decrease, total costs to society as a whole increase
(Cutler and Huckman, 2003).
The third type of medical innovation is treatment with considerable uncertainty of value
or poor cost effectiveness. The classical example is arthroscopic surgery for osteoarthritis of
the knee, a surgical procedure that can diagnose and treat problems in the knee joint.
Kirkley and their colleagues conducted a single-center, randomized, controlled trial of
arthroscopic surgery in patients with moderate-to-severe osteoarthritis of the knee. Patients
were randomly assigned to surgical lavage and arthroscopic débridement together with opti-
mized physical and medical therapy or to treatment with physical and medical therapy
alone. They found that arthroscopic surgery for osteoarthritis of the knee does provide any
additional benefit to optimized physical and medical therapy (Kirkley et al., 2008). Barnato
et al (2007) examined whether variations across regions in end-of-life (EOL) treatment
intensity are related with regional differences in patient preferences for EOL care.
They concluded that Medicare beneficiaries preferred a focus on palliative care ra-
ther than life-extension care such as ICU for the chronically ill, which increases
healthcare costs. Temel et al. (2010) argued that lung cancer patients who were
treated with the advanced medical technology experienced worse quality of life and
shorter life expectancy as compared with palliative care.
These types of innovations occur in common in health care, and lead to improvements
due to reduced healthcare costs per procedure as well as to increased healthcare costs
due to increased demand for these procedures. Even though medical innovations make an
improvement, healthcare outcomes that change healthcare delivery can be a major
contributor to rising healthcare costs. Medical innovations are valuable to patients and
society, but they generally come with a significant additional healthcare costs.
Healthcare costs and technologic innovation
Most studies argue that medical innovation is the leading driver for rising healthcare
expenditure (Wu and Shen 2014, Sorenson et al., 2013, Newhouse, 1992, Funchs and
Sox 2001, Chernew et al., 1998, Baker et al., 2003). According to Newhouse (1992),
medical innovation explains half of the increase in healthcare expenditure in the U.S.
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phone, scientific innovations always raise expenditures, even these lower prices
(Aaron, 2002). The price of laparoscopic cholecystectomy may be 25% less than
one of open cholecystectomy, but the number of both types of cholecystectomy
has increased by 60% (Legorreta et al, 1993). The growth of healthcare services
increases the impact of price per unit. The direction of causality between medical
innovation and healthcare expenditure is obvious. Baker et al. (2003) explored the
relationship between new medical technologies and healthcare spending and
utilization. The study focused on diagnostic imaging, cardiac treatment, cancer, and
newborn care technologies. The researchers found that greater availability of
medical technology is related to greater per capita use and higher spending on
healthcare services. For example, although the increased demand of angioplasty
should reduce the number of coronary bypass surgeries, the increased availability
of angioplasty is related to more bypass surgery per population among elderly
people over 65. Similarly, more magnetic resonance imaging (MRI) does not reduce
the use of computed tomography (CT) scans performed.
Hay (2003) and Wu and Shen (2014) explored the factors that increase hospital
inpatient expenditure. They found that with overall levels of economic activity, price-
level variation, healthcare labor cost, and hospital market structure, technology that
hospitals use is the critical cost driver in inpatient expenditures. According to the CBO
report (2008), the procedure for bone marrow transplantation (also called as stem cell
transplant) was used in treating a relatively small number of patients with aplastic
anemia as well as some patients with leukemia in the late 1960s. Medical innovations
in bone marrow transplantation have scaled up the group of patients who suffer from
multiple myeloma, lymphoma, sickle cell disease, and other conditions. One major
medical innovation in the 1990s was the advent of autologous transplantation that uses
the patient’s own stem cells. This medical innovation has greatly expanded the set of
patients who need this type of therapy. Another example is joint replacement. Joint
replacement surgery was introduced in the 1960. The innovated metals and plastics of
today are stronger, longer-lasting, and less subject to corrosion than earlier models, and
produce better long-term outcomes. Surgery for hip replacement performed in the U.S
has been increasing and has become more common in younger patients. Over a 10 year
period earlier in the decade, the number of hip replacements increased from 138,700 in
2000 to 310,800 in 2010. The number of hip replacements has increased by more than
double in those aged 45 to 54 to 51,900 (Wolford et al., 2015).
Medical innovation has commanded a higher price per unit of healthcare services in
the United States compared with other countries (Reinhardt et al., 2002). For example,
greater intensive care use in the U.S. was most notable with elderly people; among pa-
tients over age 85 in the U.S., intensive care was used prior to 31.5% of medical deaths
and 61.0% of surgical deaths, versus 1.9 and 8.5% of deaths, respectively, in the United
Kingdom (Wunsch et al., 2009). This does not indicate that the United Kingdom refers
too few patients to intensive care or the United States too many. Coupled with the
cost-ineffectiveness of intensive care unit (ICU) days, the increase in ICU days in the
U.S. is consistent with overall poor productivity in U.S. healthcare expenditures. The
U.S. had almost three times more cardiac surgery units and catheterization laboratories
than Canada, Germany, and other OECD countries. In 1997, the number of coronary
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compared with 15 other OECD countries (Reinhardt et al. 2002).
The U.S. tends to easily accept expensive pharmaceutical treatments that have uncertain
benefits. For example, Ezetimibe, an expensive drug to reduce plasma cholesterol levels,
was recommended as a first-line treatment, and it was proved to be relatively ineffective
at lowering cardiovascular disease. Jackevivius and her colleagues found that after adjust-
ing for purchasing-power parity, expenditures for Ezetimibe, per 100,000 population, were
higher in the U.S. than in Cananda by a factor of more than 4 (Jackevivius et al. 2008).
The per capita expenditures for ezetimibe were $.47 in the U.S. and $2.16 in
Canada, while the corresponding expenditure for stains were $56.91 in the U.S and
$50.31 in Canada.
Although innovations in medicine reduce the cost of producing health outcomes of
any given level of quality, medical innovations in quality and rapid use of those tech-
nologies lead to higher total expenditure on healthcare services. Medical innovations
may increase spending by the provision of a greater amount of healthcare services than
would have been provided otherwise.Implications for controlling rising healthcare costs
There is consensus that advanced medical technology is a major driver of increasing
healthcare expenditures. Medical technology broadly includes medical equipment,
devices, medicines, procedures, and new medical knowledge. According to the Kaiser
Family Foundation, medical technologic innovation made a contribution to at least half
of the growth in healthcare expenditures in the U.S. (Kaiser Family Foundation, 2007).
The benefits from advanced medical technologies are to increase life expectancy, to
reduce disability among patients, and to decrease the mortality from critical diseases
like heart attacks, brain cancer, and kidney failure, but the many new expensive medical
technologies make it imperative that those medical technologies are commonly used.
In order to assess the effectiveness of medical technologies, a well-coordinated,
independent and evidence-based authority needs to be established. Although the
Office of Technology Assessment (OTA) that was created in 1972 was intended to
provide objective and authoritative evaluation of the complicated technical and
scientific issues to Congress, the OIA was closed in 1995. At the moment, there is
no nationally centralized organization to analyze the costs and clinical benefits of
new medical technologies. The effectiveness of technologic evaluation is conducted
by various private and public organizations such as the Agency for Healthcare
Research and Quality (AHRQ), the Medicare Coverage Advisory Committee, and
the Department of Veterans Affairs. Professional organizations, such as the American
College of Cardiology, the American Heart Association, and the American Academy of
Obstetrics and Gynecology, evaluate and decide the clinical effectiveness of the best prac-
tices. Payers, such as insurance companies and managed care companies, also determine
their own criteria for any available assessments. Finally, healthcare providers and patients
can decide the utilization of healthcare technology regardless of the effectiveness or costs
of medical technology. The authorities that assess the clinical and economical costs as
well as benefits of medical technology are uncoordinated and dispersed throughout the
private and public sectors. To provide effective analysis of medical technology, authorities
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well-coordinated.
A free market in medical technology would mean having less regulation. It would also
mean less regulation and less subsidization to market participants, such as healthcare
providers, insurers, and healthcare consumers. Its results would increase competition
among healthcare providers and insurers, would provide more choices for healthcare
consumers, and would lower healthcare expenditures. For example, the price for LASIK
surgery has decreased to as low as $200 per eye in some areas, dropping from as high
as $4000 per eye a few years ago. Government policies induce price and service compe-
tition among service providers to mitigate increasing healthcare expenditures.
To control healthcare expenditures from overuse of medical technologies, assessment
of medical technology must be enhanced. The definition of assessment is to examine
safety, efficacy, outcome and cost, usually performed to inform coverage or benefit design
decisions (Mendelson, et al., 1995). The international Network of Agencies for Health
Technology Assessment suggests health technology assessment be used to identify
evidence on the costs and benefits of healthcare intervention, to synthesize health
research findings about the effectiveness of the different interventions, to appraise the
economic implications and analyze cost-effectiveness of intervention, and to evaluate
social and ethical implications of the diffusion and use of medical technologies as well as
the organizational implications (INAHTA, 2016). Useful and reliable information regard-
ing medical technologies must be widely disseminated to the public to reduce the demand
of medical technology from healthcare providers and consumers. After AHRQ was
established, it has become the most prominent federal agency to authorize various types
of research on the effectiveness of medical technologies in the U.S. An independent and
nonpartisan agency, wholly free from political pressure, must be created to analyze clinical
and cost-effectiveness of new medical technologies.
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